Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Carcinoma, Non-Small-Cell Lung

Non-small Cell Lung Cancer Metastatic

Neurofibromatosis 1, Neurofibrosarcoma

Uveal Melanoma, Melanoma

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Advanced Cancer

Colonic Neoplasms, Colorectal Neoplasms

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Breast Neoplasms

Locally Advanced or Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Solid Tumors

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Bile Duct Neoplasms, Carcinoma, Hepatocellular

Adult Solid Neoplasm

Adult Solid Neoplasm

Solid Tumours

Multiple Myeloma

Solid Tumours

Renal Insufficiency

Solid Tumours

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Colorectal Neoplasms

Solid Tumours

Healthy Volunteers Pharmacokinetic Study

Colonic Neoplasms, Rectal Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

DOC-MEK

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

SAFIR02_Lung

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Intermittent Selumetinib for Uveal Melanoma

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

MK-8353-014

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

MEKRT

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

A Study of ARRY-142886 in Patients With Advanced Cancer

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Selumetinib in Combination With Gefitinib in NSCLC Patients

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

ABC-04

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Selumetinib in Cancers With BRAF Mutations

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer